Journal
HAEMATOLOGICA
Volume 101, Issue 6, Pages 672-679Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2015.141796
Keywords
-
Categories
Funding
- NCI NIH HHS [K08 CA188529, P30 CA008748] Funding Source: Medline
Ask authors/readers for more resources
Wilms tumor 1 (WT1) has long been implicated in acute myeloid leukemia. It has been described to be both over-expressed and mutated in different forms of acute myeloid leukemia, and overexpression has been reported to play a prognostic role in this disease. However, the precise mechanism through which WT1 may play a role in leukemogenesis has remained elusive. In recent years, new evidence has emerged that points towards a novel role of WT1 mutations in the deregulation of epigenetic programs in leukemic cells through its interaction with TET proteins. Herein we review the current status of the field and its therapeutic and prognostic implications in acute myeloid leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available